A gastrula-like embryo model derived from stem cells and its construction method and application
By inducing human pluripotent stem cells into gastrulation model, the development process of periimplantation embryos was simulated, the problem of lack of key structure in the existing model was solved, and biological event reproduction and drug screening of early embryo development were achieved Safety testing provides a new platform for the research and treatment of early embryonic development diseases.
Patent Information
- Application Number
- CN202211135940.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-19
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-09-19
AI Technical Summary
Existing in vitro models failed to effectively simulate the development process of human periimplant embryos, lacked key structures such as bilayer embryo discs and yolk sacs, and could not fully reproduce the biological events of gastrulation development, limiting early embryo development Research on mechanisms and progress in disease diagnosis and treatment.
By inducing human pluripotent stem cells into gastrulation models, using specific medium and conditional induction methods, biological events and key structures that simulate early embryonic development, such as bilayer blastodiscs, amniotic cavity and amniotic cells, are constructed in vitro in vitro. The formation of the key characteristics of the periimplantation stage to the gastrulation stage has been reproduced.
This model is able to stably induce the formation of a structure similar to Carnegie stage 6 embryo, providing a batch-induced early embryo drug screening model for drug safety testing in early pregnancy patients and for early embryo developmental diseases Research and treatment provide a platform.
Smart Images

Figure CN116590219B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to an in vitro simulated human peri-implantation gastrula-like embryo model derived from pluripotent stem cells, and an induction method and application thereof. Background Art
[0002] Human life begins at fertilization, when sperm and egg combine to form a zygote. This unique totipotent cell undergoes continuous division and cell differentiation, forming a blastocyst on the fifth day. The blastocyst is mainly composed of two cell groups: the inner cell mass (ICM) and the trophectoderm (TE). The inner cell mass forms the embryo itself and extraembryonic tissues in later development, while the trophectoderm will further develop into the main components of the placenta. Before embryo implantation, the inner cell mass begins to differentiate into the ectoderm (EPI) and the hypoblast (HYPO). After implantation, the EPI forms the amniotic sac and the HYPO forms the yolk sac. Subsequently, the EPI undergoes gastrulation and establishes a gastrula with three germ layers. Due to technical and ethical restrictions and limited sample numbers, we have little research on human periimplantation embryonic development. Understanding the mechanisms of early human embryonic development is very important for developmental biology and regenerative medicine. Most of our current understanding of early human embryonic development comes from the study of the histology and anatomical structure of Carnegie embryos. There are still many unknown areas to explore at this stage.
[0003] At present, the research on human pre-implantation and peri-implantation embryonic development has made a breakthrough. Researchers have been able to culture human embryos in vitro to the 14th day of embryonic development before gastrulation, or to culture human naive pluripotent stem cells ( The induction of human Pluripotent Stem Cells (nhPSCs) into preimplantation embryoids, combined with single-cell multi-omics sequencing and fluorescence imaging technology, has opened up a new way to study human gastrula development and greatly expanded the understanding of the characteristics and mechanisms of early human gastrula development. Although some studies have attempted to use hPSCs to establish amniotic organoids or reconstruct the early development process of the primitive ectoderm to simulate the post-implantation embryonic development process from a three-dimensional level, the model lacks the key structures of the embryo (double-layered blastoderm, yolk sac), and the general development process of the human primitive endoderm has not been observed. Therefore, an ideal research model for peri-implantation to post-implantation gastrula embryos has not yet been established. Summary of the invention
[0004] In this study, a model and method for inducing human pluripotent stem cells (hPSCs) into gastrula-like embryos was established. The gastrula-like embryo model was constructed in vitro and simulated the biological events of early embryonic development and the key structures of the embryo to a certain extent, such as the establishment of a double-layered blastodisk, the appearance of the amniotic cavity and amniotic cells, and the appearance of the primitive streak. It was verified at both the protein level and the transcriptome level, and can well reproduce the key characteristics of embryos from the periimplantation period to the gastrula stage. In addition, the model can be induced in batches as an early embryo drug screening model, thereby providing safety testing for the use of drugs for some clinical early pregnancy patients.
[0005] The human pluripotent stem cells used in the present invention include human induced pluripotent stem cells (human inducedPluripotent Stem Cells, hiPSCs) and human embryonic stem cells (human Embryonic Stem Cells, hESCs), and the human induced pluripotent stem cells and human embryonic stem cells are already established and can be purchased through public channels. In a specific embodiment, the human induced pluripotent stem cells are purchased from: the cell bank / stem cell bank of the Chinese Academy of Sciences Typical Culture Collection Committee, the cell name is DYR0100, and the catalog number is SCSP-1301; the human embryonic stem cells are purchased from: the cell bank / stem cell bank of the Chinese Academy of Sciences Typical Culture Collection Committee, the cell name is H1, and the catalog number is SCSP-301.
[0006] The first object of the present invention is to provide a method for constructing a gastrula-like embryo model, specifically, to induce pluripotent stem cells into a human gastrula-like embryo model in vitro, comprising the following steps:
[0007] (1) When the pluripotent stem cells grow to 80-90% confluence, the cells are digested into single cells, and the cells are resuspended in PBS (phosphate buffered saline) to obtain a cell suspension 1; preferably, the cells are digested into single cells using trypsin TrypLE Select.
[0008] Take cell suspension 1 and add G1ER medium containing Y-27632 to further resuspend the cells to obtain cell suspension 2;
[0009] Inoculate cell suspension 2 into an embryoid body culture plate coated with an anti-adhesion solution in advance and centrifuge;
[0010] On the second day of culture, half of the medium was replaced with G1ER medium, and half of the medium was replaced every day until the primitive endoblastoderm and ectoblastoderm were formed;
[0011] Preferably, the ratio of the cell suspension 1 to the G1ER medium containing Y-27632 is: 7.5-9.0×10 4 Add 2 mL of G1ER medium containing Y-27632 to the cell suspension of 10 cells;
[0012] Preferably, the cell suspension 2 is inoculated with 50-75 cells per microwell;
[0013] Preferably, the centrifugation is performed using a horizontal centrifuge at 800 rpm for 2 minutes;
[0014] Preferably, the anti-adhesion solution is Anti-adhesion rinsing Solution, and the embryoid body culture plate is Agreewell400 TM Petri dish.
[0015] Preferably, step (1) is performed on day 0 to day 3 of the method for constructing a post-implantation gastruloid model.
[0016] (2) Discard 1 / 2 to 3 / 4 of the volume of the G1ER medium in each well of the culture plate (1) and add G2EE medium to perform amniotic cavity pre-induction; when adding the medium, add it slowly along the wall to prevent the already formed gastruloids from floating up from the microwells and then fusing.
[0017] In a particular embodiment, the culture plate is Agreewell 400 TM Discard 3 / 4 of the volume of G1ER culture medium in each well of the culture dish or plate, i.e. 1.75 mL / well.
[0018] Preferably, step (2) is performed on day 4 of the method for constructing the post-implantation gastruloid model.
[0019] (3) Discard 1 / 2 to 3 / 4 of the volume of the G2EE medium in each well of the culture plate (2) and add aG2EE medium to induce the formation of amnion cells; when adding the medium, add it slowly along the wall to prevent the already formed gastruloids from floating up from the microwells and then fusing.
[0020] In a particular embodiment, the culture plate is Agreewell 400 TM Discard 3 / 4 of the volume of G2EE medium in each well of the culture dish or plate, i.e. 1.75 mL / well.
[0021] Preferably, step (3) is performed on the fifth day of the method for constructing the post-implantation gastruloid model.
[0022] (4) Discard 1 / 2 to 3 / 4 of the volume of the aG2EE medium in each well of the culture plate (3) and add bG2EE medium for culturing; until amniotic cells, primitive streak cells, and primordial germ cells are induced to obtain the post-implantation gastrula model. When adding the medium, it can be added slowly and adhered to the wall to prevent the formed gastrula from floating from the microwells and then fusing.
[0023] In a particular embodiment, the culture plate is Agreewell 400 TM Discard 3 / 4 of the volume of aG2EE culture medium in each well of the culture dish or plate, i.e., 1.75 mL / well.
[0024] Preferably, step (4) is performed on day 6 to 7 of the method for constructing the post-implantation gastruloid model.
[0025] Furthermore, the culture conditions of the culture in steps (1) to (4) are: culture in an environment with a temperature of 37° C. and a volume concentration of carbon dioxide of 5 to 6%.
[0026] Furthermore, the pluripotent stem cells are induced pluripotent stem cells or embryonic stem cells; preferably, they are human induced pluripotent stem cells or embryonic stem cells.
[0027] Furthermore, the components of the G1ER medium in step (1) include:
[0028] 50% by volume of G-1 TM Plus blastomere medium, 25% Essential 8 medium, and 25% RACL medium;
[0029] The RACL culture medium comprises 95%-98.5% by volume of the basic culture medium RPMI 1640 (containing GlutaMAX), 1% by volume of the B27 additive, 0.5% by volume of the penicillin-streptomycin double antibody, 0.1 mM non-essential amino acids, 0.1 mM β-mercaptoethanol, 100 ng / mL of recombinant human activin A protein, 20 ng / mL of recombinant human leukocyte factor protein, and 3 μM CHIR 99021.
[0030] The composition of G1ER medium containing Y-27632 is as follows:
[0031] 50% by volume of G-1 TMPlus blastomere medium, 25% Essential 8 medium and 25% RACL medium; the RACL medium contains 95%-98.5% basal medium RPMI 1640 (containing GlutaMAX), 1% B27 additive by volume, 0.5% penicillin-streptomycin double antibody by volume, 0.1mM non-essential amino acids, 0.1mM β-mercaptoethanol, 100ng / mL recombinant human activin A protein, 20ng / mL recombinant human leukocyte factor protein, 3μM CHIR 99021, and 10μM Y-27632.
[0032] Furthermore, the components of the G2EE medium in step (2) include:
[0033] 50% by volume of G-2 TM Plus embryo culture medium, 25% Essential 8 culture medium and 25% EBB culture medium; the EBB culture medium contains 100% Essential 6 culture medium, 20 ng / mL recombinant human bone morphogenetic protein 4, and 10 ng / mL recombinant human fibroblast growth factor 2.
[0034] Furthermore, the components of the aG2EE medium in step (3) include:
[0035] 50% by volume of G-2 TM Plus embryo culture medium, 25% Essential 8 culture medium and 25% aEBB culture medium; the aEBB culture medium contains 100% Essential 6 culture medium, 100 ng / mL recombinant human bone morphogenetic protein 4, and 10 ng / mL recombinant human fibroblast growth factor 2.
[0036] Furthermore, the components of the bG2EE medium in step (4) include:
[0037] 50% by volume of G-2 TM Plus embryo culture medium, 25% Essential 8 culture medium and 25% bEBB culture medium; the bEBB culture medium contains 100% Essential 6 culture medium, 75 ng / mL recombinant human bone morphogenetic protein 4, and 10 ng / mL recombinant human fibroblast growth factor 2.
[0038] The second object of the present invention is to provide a gastrula-like embryo model constructed using the aforementioned method.
[0039] The third object of the present invention is to provide the aforementioned gastrula-like model, or the application of tissues or organs derived from the model or their cultures in the study of the mechanism of early human embryonic development.
[0040] The fourth object of the present invention is to provide the aforementioned gastrula model, or the use of tissues or organs derived from the model or their cultures in diagnostic strategies and / or therapeutic strategies for human early embryonic developmental diseases.
[0041] The fifth object of the present invention is to provide the aforementioned gastrula model, or the use of tissues or organs derived from the model or their cultures in screening, verifying, evaluating, assessing or studying the efficacy of drugs for preventing and / or treating human early embryonic development diseases.
[0042] Furthermore, the human early embryo development disease is drug-induced human early embryo teratogenesis.
[0043] The gastrula model of the present invention is a model in which the final state obtained by inducing pluripotent stem cells in vitro is similar to a Carnegie stage 6 embryo. The model can be induced in batches as an early embryo drug screening model, thereby providing safety testing for the use of drugs in some clinical early pregnancy patients. The gastrula model, or the tissue or organ derived from the gastrula model or its culture cannot develop into an individual due to the lack of cell types such as trophoblasts.
[0044] The technical solution of the present invention has the following advantages:
[0045] Feature 1: Human pluripotent stem cells can complete aggregation within 12 hours, have high induced stability, and have stable cell growth characteristics in continuous 7-day gastrula-like embryo culture.
[0046] Feature 2: The lineage separation of primitive endoderm and primitive ectoderm begins on day 1 of gastrula induction, and primitive endoderm-like cells appear, expressing markers of pluripotency (OCT4) and early primitive endoderm (OTX2, GATA6).
[0047] Feature 3: The typical two-germinal disc structure of the embryo appears at 3 days, and the epiblast side cells are OCT4 and SOX2 positive columnar cells, and the hypoblast side cells are OTX2, GATA6, and SOX17 positive cuboidal cells.
[0048] Feature 4: At 4-5 days after gastrula induction, the amniotic cavity structure begins to form on the Epiblast side, and some amniotic cells appear, which are positive for TFAP2a and CDX2, weakly positive for OCT4, and negative for SOX2.
[0049] Feature 5: At 6-7 days of gastrula induction, the amniotic cells separated from the Epiblast further thinned to form a distinct squamous amniotic epithelium, which was positive for amniotic cell markers such as TFAP2a and CDX2 and negative for pluripotency markers such as OCT4 and SOX2.
[0050] Feature 6: After gastrula induction, some T and EOMES-positive cells were separated from Epiblast on days 6-7, and the pluripotency marker (OCT4) was further weakened, indicating that they were undergoing the epithelial-mesenchymal (EMT) process, which was consistent with the characteristics of primitive streak production, proving that gastrulation began to initiate in gastrula after implantation.
[0051] Feature 7: A small number of primordial germ cells appear on day 6-7 of gastrula induction, showing pluripotency markers (OCT4, NANOG, NANOS3), primordial germ cells (SOX17, AP2C, BLIMP1) positive and characteristic SOX2 negative.
[0052] Feature 8: The final state of the gastrula after 7 days of induction culture is similar to that of the embryo at Carnegie stage 6.
[0053] Feature 9: This model can be induced in batches as an early embryo drug screening model, thereby providing safety testing for the use of drugs in certain clinical early pregnancy patients.
[0054] Beneficial effects: This model provides a platform for in vitro research on early human embryonic development, aims to understand the complexity of early human embryonic development, and provides a research platform for the development of clinical treatments for early embryonic periimplantation diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0055] Figure 1 This is a white light image of the culture process of the gastrula-like embryo model induced for 1-7 days provided by an embodiment of the present invention, wherein: Figure 1 A is a gastrula-like embryo induced by human induced pluripotent stem cells (hiPSCs) after implantation. Figure 1 B is the gastrula after induction and implantation of human embryonic stem cells (hESCs), the scale bar is 100 μm;
[0056] Figure 2 These are white light images of the process of sampling gastrula-like embryos induced by human induced pluripotent stem cells (hiPSCs) at 3 and 7 days after implantation, with scale bars of 50 μm and 100 μm;
[0057] Figure 3 This is a growth curve of gastrula-like embryos induced for 1-7 days provided by an embodiment of the present invention, each point represents the number of cells in a blastocyst-like embryo, and the sample size at each time point is not less than 20, wherein, Figure 3A is a growth curve of human induced pluripotent stem cells (hiPSCs) induced from day 1 to day 7. Figure 3 B is a growth curve of human embryonic stem cells (hESCs) induced for 1-7 days;
[0058] Figure 4 This is the IF of the process from the appearance of the primitive endoderm to the appearance of two embryonic disc structures from 1-3 days of induction of gastrula-like embryos provided by one embodiment of the present invention, with a scale of 20 μm; wherein, Figure 4 A is the immunofluorescence image of GATA6 and OCT4. Figure 4 B is the immunofluorescence image of SOX2 and SOX17;
[0059] Figure 5 This is the IF of the process from the formation of the amniotic cavity to the appearance of amniotic cells from the gastrula-like embryos induced for 4-7 days according to one embodiment of the present invention, with a scale of 20 μm; wherein, Figure 5 A is CDX2, OCT4 and GATA6, Figure 5 B is SOX2, TFAP2a, and SOX17;
[0060] Figure 6 This is the IF of the migration process of primitive streak of gastrula-like embryos induced for 7 days provided by one embodiment of the present invention, wherein: Figure 6 A shows that OCT4+T+ gastrula motor cells gradually transition to T+EOMES+ positive cells with definitive endoderm fate, and finally differentiate into EOMES+ definitive endoderm cells. Figure 6 B shows that OCT4+T+ gastrula motor cells gradually transition to T+MIXL1+ positive mesoderm fate cells and finally differentiate into MIXL1+ mesoderm cells, the scale bar is 50μm;
[0061] Figure 7 It is the bioinformatics analysis result provided by an embodiment of the present invention. Figure A is the UMAP clustering diagram of single-cell sequencing data when gastrula-like embryos are induced for 7 days, wherein Epiblast is primitive ectoderm, Endoderm is primitive endoderm, Primitive Streak is primitive streak, Primitive Streak anlage Epiblast is primitive streak primordium ectoderm, PGC is primordial germ cell, Amnion is amnion, and Mesoderm is mesoderm; Figure B is the basis for related clustering;
[0062] Figure 8It is the result of drug application of the gastrula model provided by one embodiment of the present invention. Figure A is a white light image of the control group, dimethyl sulfoxide, 5μM THD and 10μM THD at 7 days of gastrula and the DAPI (4',6-diamidino-2-phenylindole) staining results, with scales of 200μm and 100μm, respectively. Figure B is the amount of single gastrula cells in the control group, dimethyl sulfoxide, 5μM THD and 10μM THD at 7 days of gastrula induction. Figure C is the volume of a single gastrula in the control group, dimethyl sulfoxide, 5μM THD and 10μM THD at 7 days of gastrula induction. DETAILED DESCRIPTION
[0063] The present invention discloses a method for inducing human pluripotent stem cells into a gastrula-like model. The present invention provides a method for inducing human pluripotent stem cells into a gastrula-like model. The reagents, instruments, cell lines and the like used in the method can all be purchased from the market. The human induced pluripotent stem cells are purchased from the cell bank / stem cell bank of the Chinese Academy of Sciences Type Culture Collection Committee, with the cell name being DYR0100 and the catalog number being SCSP-1301; the human embryonic stem cells are purchased from the cell bank / stem cell bank of the Chinese Academy of Sciences Type Culture Collection Committee, with the cell name being H1 and the catalog number being SCSP-301.
[0064] (1) The sources of the culture medium components used for inducing human pluripotent stem cells into gastrula-like embryos in vitro:
[0065] G-1 TM Plus blastomere medium: 10128, purchased from Vitrolife, Sweden;
[0066] G-2 TM Plus embryo medium: 10132, purchased from Vitrolife, Sweden;
[0067] Essential 8 medium: A1517001, purchased from Gibco, USA;
[0068] Essential 6 medium: A1516401, purchased from Gibco, USA;
[0069] RPMI 1640 (containing GlutaMAX): 61870036, purchased from Gibco, USA;
[0070] Anti-adhension rinsing solution: 07010, purchased from STEMCELL, USA
[0071] B27 additive: 12587-010, purchased from Gibco, USA;
[0072] Non-essential amino acids, MEM non-essential amino acids, 11140076, purchased from Gibco, USA;
[0073] β-Mercaptoethanol: 21985023, purchased from Gibco, USA;
[0074] Recombinant human bone morphogenetic protein 4: 314-BP, purchased from R&D Systems, USA;
[0075] Recombinant human leukemia inhibitory factor: 225-SC, purchased from R&D Systems, USA;
[0076] Recombinant human activin A protein: 338-AC, purchased from R&D Systems, USA;
[0077] Recombinant human fibroblast growth factor 2: 3718-FB, purchased from R&D Systems, USA;
[0078] ROCK inhibitors: specific types are Y27632 and HY-10071, purchased from MCE, USA;
[0079] CHIR99021: The specific type is Laduviglusib trihydrochloride, HY-10182B, purchased from MCE Company in the United States.
[0080] (2) Preparation of G1ER medium:
[0081] 50% by volume of G-1 TM Plus blastomere medium, 25% Essential 8 medium and 25% RACL medium; the RACL medium contains 98.5% by volume of basal medium RPMI 1640 (containing GlutaMAX), 1% by volume of B27 additive, 0.5% by volume of penicillin-streptomycin double antibody, 0.1 mM non-essential amino acids, 0.1 mM β-mercaptoethanol, 100 ng / mL recombinant human activin A protein, 20 ng / mL recombinant human leukocyte factor protein, and 3 μM CHIR 99021.
[0082] (3) Preparation of G1ER medium containing Y-27632:
[0083] 50% by volume of G-1 TMPlus blastomere medium, 25% Essential 8 medium and 25% RACL medium; the RACL medium contains 98.5% basal medium RPMI 1640 (containing GlutaMAX), 1% B27 additive by volume, 0.5% penicillin-streptomycin double antibody by volume, 0.1mM non-essential amino acids, 0.1mM β-mercaptoethanol, 100ng / mL recombinant human activin A protein, 20ng / mL recombinant human leukocyte factor protein, 3μM CHIR 99021, and 10μM Y-27632.
[0084] (4) Preparation of G2EE medium:
[0085] 50% by volume of G-2 TM Plus embryo culture medium, 25% Essential 8 culture medium and 25% EBB culture medium; the EBB culture medium contains 100% Essential 6 culture medium, 20 ng / mL recombinant human bone morphogenetic protein 4, and 10 ng / mL recombinant human fibroblast growth factor 2.
[0086] (5) Preparation of aG2EE culture medium:
[0087] 50% by volume of G-2 TM Plus embryo culture medium, 25% Essential 8 culture medium and 25% aEBB culture medium; the aEBB culture medium contains 100% Essential 6 culture medium and multiple cytokines: 100 ng / mL recombinant human bone morphogenetic protein 4, 10 ng / mL recombinant human fibroblast growth factor 2.
[0088] (6) Preparation of bG2EE medium:
[0089] 50% by volume of G-2 TM Plus embryo culture medium, 25% Essential 8 culture medium and 25% bEBB culture medium; the bEBB culture medium contains 100% Essential 6 culture medium and multiple cytokines: 75 ng / mL recombinant human bone morphogenetic protein 4, 10 ng / mL recombinant human fibroblast growth factor 2.
[0090] Example 1 Induction of gastrula-like embryos from human induced pluripotent stem cells (iPSCs) (stage 1): Days 0-3, formation of primitive endoblast and ectoblast
[0091] When human induced pluripotent stem cells DYR0100 grow to 80-90% confluence, the cells are digested into single cells using TrypLE Select, and the cells are resuspended in PBS to obtain cell suspension 1;
[0092] Take 9.0x10 4 2 mL of G1ER medium containing Y-27632 was added to the cell suspension 1 of 10 cells to resuspend the cells to obtain cell suspension 2;
[0093] Inoculate cell suspension 2 into Agreewell 400 coated with anti-adhesion rinsing solution in advance. TM In one well of the culture dish, after centrifugation at 800 rpm for 2 minutes, the cell volume per microwell was 75 cells (Agreewell 400 TM Each well of the culture dish has 1200 microwells, that is, the cell volume of each microwell is 9.0x10 4 / 1200=75);
[0094] On the second day of culture, G1ER medium was used and half of the medium was replaced every day until the third day of culture to form the primitive endoblast and ectoblast.
[0095] Example 2 Induction of gastrula-like embryos from human induced pluripotent stem cells (hiPSCs) (stage 2): Day 4, amniotic cavity pre-induction
[0096] Discard 3 / 4 volume of the first-stage G1ER medium / well, i.e. 1.75 mL / well, and then slowly add the second-stage G2EE medium to the wells to prevent the formed gastruloids from floating up from the microwells and then fusing, so as to perform amniotic cavity pre-induction.
[0097] Example 3 Induction of gastrula-like embryos from human induced pluripotent stem cells (hiPSCs) (three stages): Day 5, induction of amniotic cells
[0098] Discard 3 / 4 volume of the second-stage G2EE medium / well, i.e. 1.75 mL / well, and then slowly add the third-stage aG2EE medium to the wells to prevent the formed gastruloids from floating up from the microwells and then fusing, thereby inducing the formation of amnion cells.
[0099] Example 4 Induction of gastrula-like embryos from human induced pluripotent stem cells (hiPSCs) (four stages): Day 6-7, induction of amniotic cells, primitive streak cells, and primordial germ cells
[0100] Discard 3 / 4 volume / well of the third-stage aG2EE medium, and slowly add the fourth-stage bG2EE medium (1.75 mL / well) after the wells adhere to the wall to prevent the formed gastruloids from floating up from the microwells and then fusing. After 24 hours, continue to change the medium (bG2EE medium) by 1.75 mL, and culture to the 7th day to induce amniotic cells, primitive streak cells, and primordial germ cells to obtain the post-implantation gastruloid model.
[0101] Example 5 Inducing gastrula-like embryos from human embryonic stem cells (hESCs), repeating the experimental contents of Examples 1-4
[0102] (1) Day 0-3, the primitive endoblast and ectoblast are formed:
[0103] When human embryonic stem cells H1 grow to 80-90% confluence, the cells are digested into single cells using TrypLE Select, and the cells are resuspended in PBS to obtain cell suspension 1;
[0104] Take 9.0x10 4 2 mL of G1ER medium containing Y-27632 was added to the cell suspension 1 of 10 cells to resuspend the cells to obtain cell suspension 2;
[0105] Inoculate cell suspension 2 into Agreewell 400 coated with anti-adhesion rinsing solution in advance. TM In one well of the culture dish, after centrifugation at 800 rpm for 2 minutes, the cell volume per microwell was 75 cells (Agreewell 400 TM Each well of the culture dish has 1200 microwells, that is, the cell volume of each microwell is 9.0x10 4 / 1200=75);
[0106] On the second day of culture, G1ER medium was used and half of the medium was replaced every day until the third day of culture to form the primitive endoblast and ectoblast.
[0107] (2) Day 4, amniotic cavity pre-induction:
[0108] Discard 3 / 4 volume of the first-stage G1ER medium / well, i.e., 1.75 mL / well, and then slowly add the second-stage G2EE medium to the wells to prevent the formed gastruloids from floating up from the microwells and then fusing, and perform amniotic cavity pre-induction;
[0109] (3) Day 5, amniotic cell induction:
[0110] Discard 3 / 4 volume of the second-stage G2EE medium / well, i.e. 1.75 mL / well, and then slowly add the third-stage aG2EE medium to the wells to prevent the formed gastruloids from floating up from the microwells and then fusing, thereby inducing the formation of amnion cells.
[0111] (4) Day 6-7: Induction of amniotic cells, primitive streak cells, and primordial germ cells:
[0112] Discard 3 / 4 volume / well of the third-stage aG2EE medium, and slowly add the fourth-stage bG2EE medium (1.75 mL / well) after the wells adhere to the wall to prevent the formed gastruloids from floating up from the microwells and then fusing. After 24 hours, continue to change the medium (bG2EE medium) by 1.75 mL, and culture to the 7th day to induce amniotic cells, primitive streak cells, and primordial germ cells to obtain the gastruloid model.
[0113] Example 6 Verification of the biological characteristics of gastrula-like embryos induced by human induced pluripotent stem cells (hiPSCs)
[0114] 1.1 Morphological observation of induced gastrula-like embryos
[0115] The gastrula models induced in the culture dishes for 1-7 days in Examples 1 to 4 were observed under an upright fluorescence microscope. It can be seen that the cells grew rapidly, the volume of the gastrula gradually increased, and there was an obvious two-germ disc arrangement structure at 3 days, an amniotic cavity structure appeared at 4-5 days, and a yolk sac structure appeared in some gastrula models at 4-7 days. The diameter of the gastrula model at 7 days ranged from about 250 to 350 μm. The morphological observation results are as follows: Figure 1 A and Figure 2 shown.
[0116] 1.2 Determination of the growth curve of gastruloid embryos after induction and implantation
[0117] 1.2.1 Growth curve determination steps
[0118] During the 1-7 days of induction in the culture dish in Examples 1 to 4, samples were collected every 24 hours;
[0119] After the samples were collected, they were fixed with 4% paraformaldehyde for 30 minutes, the fixative was discarded, and PBS was added for washing 3 times, 5 minutes each time;
[0120] Then, the cells were blocked with 5% bovine serum albumin (containing 1% tTriton) at room temperature for 4 h;
[0121] Then, DAPI was diluted at a ratio of 1:200 and stained at room temperature for 4 h;
[0122] After discarding the DAPI diluent, add PBS to wash 3 times, 5 minutes each time, move the sample into the chamber staining chamber, and add a certain amount of prepared iohexol solution for transparency. Cover the chamber with a slide and use a confocal microscope to take pictures;
[0123] After shooting, the parameters were adjusted using IMARIS software to perform single sample counting, with 20-36 replicates for each day's samples.
[0124] 1.2.2 Growth curve results
[0125] The measurement was continued for 7 days, and the growth curve data shown in Table 1 below were obtained.
[0126] Table 1 shows the growth curve data obtained from 7 consecutive days of measurement, with 20-35 replicates for each day.
[0127]
[0128]
[0129]
[0130] Based on the cell growth curve data in Table 1, we obtained Figure 3 A is a schematic diagram of the growth curve of gastrula-like embryos after induced implantation. Figure 3 The horizontal axis is the induction culture time (days), and the vertical axis is the number of cells in a single gastrula.
[0131] Refer to the growth curve data in Table 1 and Figure 3 The growth curve diagram shown in A shows that the cells in the gastrula proliferate steadily, increasing from 50-75 cells / cell at the initial 0 day to 1040 cells / cell at 7 days.
[0132] In summary, the induced gastrula-like cells proliferate rapidly, the cells grow actively, the cell activity state is good, the cell induction stability is high, and the in vitro induced cells have stable cell growth characteristics.
[0133] 1.3 Immunofluorescence (IF)
[0134] 1.3.1 Immunofluorescence identification process
[0135] During the 1-7 days of induction in the culture dish in Examples 1 to 4, samples were collected every 24 hours;
[0136] Fix with 4% paraformaldehyde for 30 minutes, discard the fixative and wash with PBST for 3 times, 5 minutes each time;
[0137] Blocking was performed using 5% bovine serum albumin (containing 1% tTriton) at room temperature for 4 h;
[0138] Discard the blocking solution, add the diluted antibody in proportion, and incubate at 4°C for 24 hours;
[0139] After discarding the primary antibody, wash with PBS (containing 1% Triton) for 3 times, 5 minutes each time, add the diluted secondary antibody and DAPI, and incubate at room temperature for 4 hours;
[0140] After discarding the secondary antibody, wash with PBS (containing 1% Triton) for 3 times, 5 minutes each time, move the sample into the chamber staining chamber, and add a certain amount of prepared iohexol solution for transparency. Cover the chamber chamber lightly with a slide and use a confocal microscope to photograph.
[0141] 1.3.2 Immunofluorescence identification results
[0142] Immunofluorescence identification results Figure 4-Figure 6 shown.
[0143] On day 1 of induction, a small number of GATA6 and OCT4 double-positive cells appeared, mixed in the primitive ectoderm positive for OCT4 and SOX2, indicating that the lineage of the primitive endoderm began to differentiate; on day 2 of induction, the number of GATA6-positive cells began to increase, and SOX17-positive cells appeared at the same time, and this type of cells gradually separated from the primitive ectoderm, further indicating an increase in primitive endoderm cells; on day 3 of induction, the primitive endoderm cells positive for GATA6 and SOX17 were completely separated from the primitive ectoderm cells positive for OCT4 and SOX2, and two neatly arranged embryonic disc structures were formed between the two cell types, in which the primitive ectoderm nuclei showed columnar stereoscopic cells, and the primitive endoderm nuclei showed short columnar cells ( Figure 4 ).
[0144] At 4-5 days of induction, a cavity-like structure gradually appeared on the side of the primitive ectoderm, which was consistent with the characteristics of the amniotic cavity, and cells that were positive for transcription factor 2a (TFAP2a), CDX2, and OCT4 and negative for SOX2 appeared, becoming early amniotic cells. At 6-7 days of induction, mature amniotic cells that were positive for TFAP2a, CDX2, and negative for OCT4 and SOX2 appeared, and the morphology of the cell nucleus became flat, similar to mature squamous amniotic epithelial cells ( Figure 5 ).
[0145] At 6-7 days of induction, T, EOMES and MIXL1 positive cells appeared in the OCT4 positive columnar primitive ectoderm, and the OCT4 positive expression gradually weakened, similar to the primitive streak cells, proving that the gastrula-like embryos began to undergo epithelial-mesenchymal transition (EMT) and gastrulation ( Figure 6 ).
[0146] 1.4 RNA sequencing identification
[0147] 1.4.1 RNA sequencing identification steps
[0148] In Examples 1 to 4, gastruloid embryos on the 7th day of induction were sampled from the culture dishes;
[0149] Remove the culture medium, wash the gastrula at least twice with PBS (0.01M, pH 7.4) to remove the old culture medium and the detached dead cell debris, digest with 2 mL of 0.24% Trypsin, place at 37°C for 3 minutes, and gently blow with a pipette to blow the gastrula into a single cell, then terminate the digestion with a culture medium containing serum;
[0150] Centrifuge at 1000 rpm for 5 minutes, remove the supernatant, resuspend in PBS and transfer to an enzyme-free EP tube for testing.
[0151] 1.4.2 RNA sequencing identification results
[0152] The data of gastrula embryos on the 7th day of induction were analyzed and clustered. The results showed that the cultured gastrula embryos were divided into 7 major groups, namely primitive ectoderm, primitive endoderm, primitive streak primordium cells, primitive streak, primitive germ cells, amnion and mesoderm, and the co-localization results of 3 known related specific markers were used for verification. Among them, POIU5F1, SOX2, and DNMT3B defined primitive ectoderm; HNF4A, FOXA2, and PDGFRA defined primitive endoderm; TFAP2A, ISL1, and ABCG2 defined amnion; TBXT, EOMES, and MIXL1 defined primitive streak precursor cells and primitive streak; HAND1, BMP4, and SNAI2 defined mesoderm-related and PRDM1, TFAP2C, and NANOG defined primitive germ cells ( Figure 7 ).
[0153] Example 7 Verification of the biological characteristics of gastrula-like embryos induced by human embryonic stem cells (hESCs)
[0154] 1.3 1.1 Observation of gastruloid morphology after induction and implantation
[0155] The gastrula model induced in the culture dish for 1-7 days in Example 5 was observed under an upright fluorescence microscope. It can be seen that the cells grew rapidly, the volume of the gastrula gradually increased, and there was an obvious two-germ disc arrangement structure at 3 days. The amniotic cavity structure appeared at 4-5 days, and the yolk sac structure appeared in some gastrula models at 4-7 days. The diameter of the gastrula model at 7 days ranged from about 250-350 μm. The morphological observation results are as follows: Figure 1 As shown in B.
[0156] 1.2 Determination of the growth curve of gastruloid embryos after induction and implantation
[0157] 1.2.1 Growth curve determination steps
[0158] During the 1-7 days of induction in the culture dish in Example 5, samples were collected every 24 hours;
[0159] After the samples were collected, they were fixed with 4% paraformaldehyde for 30 minutes, the fixative was discarded, and PBS was added for washing 3 times, 5 minutes each time;
[0160] Then, the cells were blocked with 5% bovine serum albumin (containing 1% Triton) at room temperature for 4 h;
[0161] Then, DAPI was diluted at a ratio of 1:200 and stained at room temperature for 4 h;
[0162] After discarding the DAPI diluent, add PBS to wash 3 times, 5 minutes each time, move the sample into the chamber staining chamber, and add a certain amount of prepared iohexol solution for transparency. Cover the chamber with a slide and use a confocal microscope to take pictures;
[0163] After shooting, the IMARIS software was used to set and adjust the parameters for single sample counting. There were 20-36 replicates for each day's samples.
[0164] 1.2.2 Growth curve results
[0165] The measurement was continued for 7 days, and the growth curve data shown in Table 1 below were obtained.
[0166] Table 2 shows the growth curve data obtained from 7 consecutive days of measurement, with 30-37 replicates for each day.
[0167]
[0168]
[0169] Based on the cell growth curve data in Table 2, we obtained Figure 3 B is a schematic diagram of the growth curve of the induced gastrula embryo. Figure 3 The horizontal axis of B is the induction culture time (days), and the vertical axis is the number of cells in a single gastrula.
[0170] Please refer to the growth curve data in Table 1 and Figure 3 As shown in the schematic diagram of the growth curve, it can be seen that the cells in the gastrula proliferate steadily, increasing from 50-75 cells / cell at the initial 0 day to 986 cells / cell at 7 days.
[0171] In summary, the induced gastrula-like cells proliferate rapidly, the cells grow actively, the cell activity state is good, the cell induction stability is high, and the in vitro induced cells have stable cell growth characteristics.
[0172] Example 8 Application of an in vitro gastrula-like induction model derived from human pluripotent stem cells
[0173] Thalidomide was selected for the model test of drugs causing early embryonic teratogenicity. Two gradients of 5 μM and 10 μM were selected, and a blank control group and a dimethyl sulfoxide group (thalidomide dissolving agent) were added for the test.
[0174] When human induced pluripotent stem cells DYR0100 grow to 80-90% confluence, the cells are digested into single cells using TrypLE Select, and the cells are resuspended in PBS to obtain cell suspension 1;
[0175] Take 9.0x10 4 2 mL of G1ER medium containing Y-27632 was added to the cell suspension 1 of 10 cells, and the cells were resuspended, and then 5 μM, 10 μM 1‰ thalidomide dimethyl sulfoxide solution and a blank control group were added respectively, a total of 4 groups, to obtain cell suspension 2;
[0176] Re-inoculate cell suspension 2 into Agreewell 400 coated with anti-adhesion rinsing solution. TM In one well of the culture dish, after centrifugation at 800 rpm for 2 minutes, the cell volume per microwell was 50-75 cells (Agreewell 400 TM Each well of the culture dish has 1200 microwells, that is, the cell volume of each microwell is 9.0x10 4 / 1200=75);
[0177] On the second day of culture, half of the medium was replaced with G1ER medium, and 5 μM and 10 μM 1‰ thalidomide, dimethyl sulfoxide solution, and blank control were added, and half of the medium was replaced every day until the third day of culture;
[0178] When the first stage of induction was completed, samples from the four groups were collected, fixed with 4% paraformaldehyde for 30 minutes after white light recording, and related immunofluorescence staining was performed for statistical verification;
[0179] After culturing for 3 days, discard 1.75 mL of the first-stage G1ER medium and slowly add the second-stage G2EE medium to the cells, and add 5 μM and 10 μM 1‰ thalidomide, dimethyl sulfoxide solution, and blank control, respectively, to prevent the formed gastruloids from floating from the microwells and then fusing;
[0180] When the culture reached 4 days, 1.75 mL of the second-stage G2EE medium was discarded, and the third-stage aG2EE medium was slowly added to the cells, and 1‰ thalidomide and dimethyl sulfoxide solutions containing 5 μM and 10 μM, respectively, as well as a blank control were added to prevent the formed gastruloids from floating from the microwells and then fusing;
[0181] On the fifth day of culture, 1.75 mL of the third-stage aG2EE medium was discarded, and the fourth-stage bG2EE medium was slowly added to the cells, and 5 μM and 10 μM 1‰ thalidomide, dimethyl sulfoxide solution, and a blank control were added to prevent the formed gastruloids from floating from the microwells and then fusing. After 24 hours, the medium (bG2EE medium) was replaced by 1.75 mL and cultured until the seventh day;
[0182] When the four-stage induction was completed, samples were collected from the four groups, and after white light recording, the cells were fixed with 4% paraformaldehyde for 30 minutes, and relevant cell nucleus staining was performed for statistical verification.
[0183] The results of the 7-day white light sampling clearly showed that the gastrula embryos in the drug-treated group were smaller in size than those in the control group, and lacked a cavity structure inside. By further marking the nucleus with DAPI staining, it was found that compared with the control group, the gastrula embryos in the drug-treated group showed a relatively disordered structure inside, and could not form an amniotic cavity and yolk sac, and only germ layer separation occurred ( Figure 8 A).
[0184] At the same time, the cell number and volume of individual gastrulae in the control group and the drug-added group were further counted and statistically analyzed. It was found that with the increase of drug concentration, the cell number and volume of gastrulae decreased, and there was a significant statistical difference compared with the blank control group and the dimethyl sulfoxide control group ( Figure 8 B, C).
[0185] It can be seen that the gastrula model, or tissues or organs derived from the model or cultures thereof can be used to screen, verify, evaluate, assess or study the efficacy of drugs for preventing and / or treating human early embryonic development diseases.
[0186] Although the present invention has been described to a certain extent, it is obvious that appropriate changes in various conditions can be made without departing from the spirit and scope of the present invention. It is understood that the present invention is not limited to the described embodiments, but belongs to the scope of the claims, which includes equivalent replacements for each of the described factors. The present specification and its drawings are illustrative and do not constitute a limitation of the claims. The scope of protection of the present invention is defined by the claims and their equivalents. The present specification contains multiple inventive concepts, such as "preferably", "according to a preferred embodiment" or "optionally", all of which indicate that the corresponding paragraph discloses an independent concept, and the applicant reserves the right to file a divisional application based on each inventive concept. Throughout the text, the features guided by "preferably" are only an optional method and should not be understood as having to be set, so the applicant reserves the right to abandon or delete the relevant preferred features at any time.
Claims
1. A method for constructing a gastrula-like embryo model, characterized in that: The following steps are included: (1) When the pluripotent stem cells grow to 80-90% confluence, the cells are digested into single cells and resuspended in PBS to obtain cell suspension 1; Take cell suspension 1 and add G1ER medium containing Y-27632 to further resuspend the cells to obtain cell suspension 2; Inoculate cell suspension 2 into an embryoid body culture plate coated with an anti-adhesion solution in advance, and centrifuge; On the second day of culture, half of the medium was replaced with G1ER medium, and half of the medium was replaced every day until the primitive endoblastoderm and ectoblastoderm were formed; (2) Discard 1 / 2 to 3 / 4 of the volume of the G1ER medium in each well of the culture plate (1) and add G2EE medium to perform amniotic cavity pre-induction; (3) Discard 1 / 2 to 3 / 4 of the volume of the G2EE medium in each well of the culture plate (2) and add aG2EE medium to induce the formation of amniotic cells; (4) Discard 1 / 2 to 3 / 4 of the volume of aG2EE medium in each well of the culture plate (3) and add bG2EE medium for culturing until amniotic cells, primitive streak cells, and primordial germ cells are induced to obtain a post-implantation gastrula-like embryo model; The components of the G1ER medium in step (1) include: 50% by volume of G-1 TM Plus blastomere medium, 25% Essential 8 medium, and 25% RACL medium; The RACL culture medium comprises: 95%-98.5% basal medium RPMI 1640 containing GlutaMAX, 1% B27 supplement, 0.5% penicillin-streptomycin, 0.1 mM non-essential amino acids, 0.1 mM β-mercaptoethanol, 100 ng / ml recombinant human activin A protein, 20 ng / ml recombinant human leukocyte factor protein, 3 μM CHIR99021; The composition of G1ER medium containing Y-27632 is as follows: 50% by volume of G-1 TM Plus blastomere medium, 25% Essential 8 medium and 25% RACL medium; the RACL medium contains 95%-98.5% basal medium RPMI 1640 containing GlutaMAX, 1% B27 additive by volume, 0.5% penicillin-streptomycin double antibody by volume, 0.1 mM non-essential amino acids, 0.1 mM β-mercaptoethanol, 100 ng / ml recombinant human activin A protein, 20 ng / ml recombinant human leukocyte factor protein, 3 μM CHIR 99021, and 10 μM Y-27632; The components of the G2EE medium in step (2) include: 50% by volume of G-2 TM Plus embryo medium, 25% Essential 8 medium and 25% EBB medium; the EBB medium contains 100% Essential 6 medium, 20 ng / ml recombinant human bone morphogenetic protein 4, and 10 ng / ml recombinant human fibroblast growth factor 2; The components of the aG2EE culture medium in step (3) include: 50% by volume of G-2 TM Plus embryo medium, 25% Essential 8 medium and 25% aEBB medium; the aEBB medium contains 100% Essential 6 medium, 100 ng / ml recombinant human bone morphogenetic protein 4, and 10 ng / ml recombinant human fibroblast growth factor 2; The components of the bG2EE medium in step (4) include: 50% by volume of G-2 TM Plus embryo medium, 25% Essential 8 medium and 25% bEBB medium; the bEBB medium contains 100% Essential 6 medium, 75 ng / ml recombinant human bone morphogenetic protein 4, and 10 ng / ml recombinant human fibroblast growth factor 2.
2. The construction method according to claim 1, characterized in that: The ratio of the cell suspension 1 to the G1ER medium containing Y-27632 in step (1) is: 7.5-9.0×10 4 Add 2 ml of G1ER medium containing Y-27632 to the cell suspension of 10 cells.
3. The construction method according to claim 1, characterized in that: The amount of cells inoculated in each microwell of the cell suspension 2 in step (1) is 50-75 cells.
4. The construction method according to claim 1, characterized in that: The pluripotent stem cells are induced pluripotent stem cells or embryonic stem cells.
5. The construction method according to claim 4, characterized in that: The pluripotent stem cells are human induced pluripotent stem cells or embryonic stem cells.
